Uncertain Future for CVRs?
Up-Front Milestone Balance Shifting in Biotechs' Favor
By Brian Orelli
Monday, August 29, 2011
For years, biotechs seeking to out-license their drug candidates have had to retain an increasing portion of the development risk.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.